tiprankstipranks
Analyst Profile
Followed by 11 other investors
.
Matthew Caufield

Matthew Caufield

H.C. Wainwright
Wall Street Analyst
Ranked #1,772 out of 8,047 Analysts on TipRanks (#3,219 out of 21,521 overall experts)

Success Rate

62%
13 out of 21 Profitable Transactions

Average Return

21.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Matthew Caufield's ratings since 2022 and opened each position for the duration of 1 Year:
61.90% of your transactions would have been profitable with an average return of 21.2%

Stock Rating Distribution

26Ratings
96.15% Buy
3.85% Hold
0.00% Sell
Distribution of Matthew Caufield's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Aldeyra Therapeutics
(ALDX)
Rating Type:Buy
Dates:May 06, 2022 - Jan 01, 1970
Gain:175.60%
The most profitable rating made by Matthew Caufield

Matthew Caufield's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Gemini Therapeutics
Mar 11, 2022
Hold
Downgraded
$2.00
(13.64% Upside)
33%
-21.70%
4
Ocuphire Pharma
May 20, 2022
Buy
Reiterated
$26.00
(923.62% Upside)
40%
-14.62%
7
IVERIC bio
Jul 27, 2022
Buy
Reiterated
$26.00
(92.88% Upside)
67%
+11.58%
8
Aldeyra Therapeutics
Aug 08, 2022
Buy
Reiterated
$15.00
(100.80% Upside)
100%
+91.42%
5
Oyster Point Pharma
Aug 12, 2022
Buy
Reiterated
$20.00
(185.31% Upside)
50%
+28.40%
2
List of latest recommendations made by Matthew Caufield. Click to expand and see Matthew Caufield's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More